Ipsel Receives Patent Approval for Low-Immunogenic Universal iPSCs
Secured intellectual property rights for HLA gene-editing technology
"Built a foundation for developing next-generation cell therapies"
"Last year’s clinical-grade iPSC supply contracts worth 6 billion won"
Ipsel, a regenerative medicine company based on induced pluripotent stem cells (iPSCs), has received a decision to register a patent for a universal iPSC manufacturing technology designed to reduce immune responses. The company plans to expand its development of cell therapies and its cell line supply business based on its proprietary cell technology.
Ipsel announced on October 14 that it had received a decision to register a domestic patent for “Low-Immunogenic Universal Induced Pluripotent Stem Cells.”
The patented technology involves editing human leukocyte antigen (HLA) genes, which are involved in immune responses, to develop iPSCs that can be used in multiple patients. The related research findings were published in the international journal Experimental & Molecular Medicine in March 2025.
Ipsel is applying the technology to develop next-generation chondrocyte therapies while also expanding its cell line supply business. The clinical-grade iPSC cell line supply contracts signed last year with Asan Medical Center, Eticstem, and Cellroid are worth approximately 6 billion won, including milestones. The company said cumulative revenue from its cell line supply business over the past three years totaled 2 billion won.
Ipsel is currently conducting clinical research on MIUChon, a cell therapy for osteoarthritis. A next-generation cartilage therapy based on universal iPSCs is being pursued as a separate follow-up development program.
Hot Picks Today
A 12-Year-Old Girl Went to the Hospital After Her Blood Pressure Hit 225 and Was Stunned: "What Is This Coral Reef-Like Thing in Her Aorta?"
- "Samsung Electronics Employees Commute by Shuttle Bus"... More Than 5,000 Homes to Be Supplied in Seoul and Busan [Real Estate A to Z]
- "Hey, Lady, Teach Your Kids to Behave!" ... 300,000 Won in Cash and a Bodily Injury Claim Demanded Over Child's Door Ding
- "If This Airs, I'm Dead"... Why a Restaurant Refused to Let Jeon Hyunmoo's Show Film
- “I Thought Surely They Wouldn’t, but Grown Adults Did This”... Wedding Shoot Atop Tomb Sparks Controversy
Nam Yujun, vice president of Ipsel, said, “We will broaden the applications of our iPSC platform by connecting our low-immunogenic cell line technology to both therapeutic development and cell line supply.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
